Therapeutic Drug Monitoring of Antiarrhythmic Drugs. Rationale and Current Status

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1990 Feb 1

PMID 2180615

Citations 4

Authors

R Latini

A P Maggioni

A Cavalli

Affiliations

Soon will be listed here.

Citing Articles

Therapeutic drug monitoring of antiarrhythmic drugs.

Jurgens G, Graudal N, Kampmann J Clin Pharmacokinet. 2003; 42(7):647-63.

PMID: 12844326 DOI: 10.2165/00003088-200342070-00004.

Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule.

Voicu V, Mircioiu C, Jinga M, Ionescu M, Burcea X, Ionescu D Eur J Drug Metab Pharmacokinet. 1994; 19(1):33-6.

PMID: 7957449 DOI: 10.1007/BF03188820.

Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Bauman J, Schoen M, Hoon T Clin Pharmacokinet. 1991; 20(2):151-66.

PMID: 2029806 DOI: 10.2165/00003088-199120020-00006.

Clinical relevance of cimetidine drug interactions.

Shinn A Drug Saf. 1992; 7(4):245-67.

PMID: 1524698 DOI: 10.2165/00002018-199207040-00002.

References

Harrison D . Current classification of antiarrhythmic drugs as a guide to their rational clinical use. Drugs. 1986; 31(2):93-5. DOI: 10.2165/00003495-198631020-00001. View

Mitchell L, Duff H, Manyari D, Wyse D . A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med. 1987; 317(27):1681-7. DOI: 10.1056/NEJM198712313172701. View

Clague H, Carruthers S . An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit. 1983; 5(3):249-54. DOI: 10.1097/00007691-198309000-00003. View

COUMEL P, FIDELLE J . Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J. 1980; 100(6 Pt 2):1063-9. DOI: 10.1016/0002-8703(80)90214-8. View

BIGGER Jr J, Fleiss J, KLEIGER R, Miller J, Rolnitzky L . The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984; 69(2):250-8. DOI: 10.1161/01.cir.69.2.250. View

Whiting B, Kelman A, Bryson S, Derkx F, Thomson A, Fotheringham G . Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. Br Med J (Clin Res Ed). 1984; 288(6416):541-5. PMC: 1444562. DOI: 10.1136/bmj.288.6416.541. View

Vlay S . How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 University Medical Centers. Am Heart J. 1985; 110(4):904-12. DOI: 10.1016/0002-8703(85)90485-5. View

Hoffman B, Dangman K . The role of antiarrhythmic drugs in sudden cardiac death. J Am Coll Cardiol. 1986; 8(1 Suppl A):104A-109A. DOI: 10.1016/s0735-1097(86)80036-5. View

Heger J, Solow E, Prystowsky E, Zipes D . Plasma and red blood cell concentrations of amiodarone during chronic therapy. Am J Cardiol. 1984; 53(7):912-7. DOI: 10.1016/0002-9149(84)90524-1. View

10.

Bonati M, Castelli D, Leone N, Perucca E, Tognoni G . Quality control in antiepileptic drug monitoring in Italy. Drug Intell Clin Pharm. 1985; 19(12):913-5. DOI: 10.1177/106002808501901208. View

11.

. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321(6):406-12. DOI: 10.1056/NEJM198908103210629. View

12.

Gottlieb S, Achuff S, Mellits E, Gerstenblith G, Baughman K, Becker L . Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. Circulation. 1987; 75(4):792-9. DOI: 10.1161/01.cir.75.4.792. View

13.

Maron B, Savage D, Wolfson J, Epstein S . Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981; 48(2):252-7. DOI: 10.1016/0002-9149(81)90604-4. View

14.

Myerburg R, Kessler K, Zaman L, Fernandez P, DeMarchena E, Castellanos A . Pharmacologic approaches to management of arrhythmias in patients with cardiomyopathy and heart failure. Am Heart J. 1987; 114(5):1273-9. DOI: 10.1016/0002-8703(87)90216-x. View

15.

Siddoway L, Woosley R . Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet. 1986; 11(3):214-22. DOI: 10.2165/00003088-198611030-00003. View

16.

Friedman L . Can chronic antidysrhythmic treatment prevent sudden death?. Eur Heart J. 1984; 5 Suppl B:99-101. DOI: 10.1093/eurheartj/5.suppl_b.99. View

17.

Woosley R, Funck-Brentano C . Overview of the clinical pharmacology of antiarrhythmic drugs. Am J Cardiol. 1988; 61(2):61A-69A. DOI: 10.1016/0002-9149(88)90741-2. View

18.

Woosley R, Roden D, Dai G, Wang T, Altenbern D, Oates J . Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther. 1986; 39(3):282-7. DOI: 10.1038/clpt.1986.40. View

19.

. The role of programmed electrical stimulation in evaluation of investigational antiarrhythmic drugs. Circulation. 1986; 73(2 Pt 2):II1-113. View

20.

Kates R . Plasma level monitoring of antiarrhythmic drugs. Am J Cardiol. 1983; 52(6):8C-13C. DOI: 10.1016/0002-9149(83)90626-4. View